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MyogeninClass IIa HDACs including HDAC7 play a role in gene expression, cell differentiation, and animal development
through their association with transcription factors such as myogenic enhancer factors 2 (MEF2s). In this
study, we show that endogenous HDAC7 localizes to both the nucleus and the cytoplasm of C2C12 myoblasts
but is exclusively retained in the cytoplasm of myotubes after completion of differentiation process. To
elucidate the role of differential distribution of HDAC7 during myogenesis, we examined the effects of stably
expressed HDAC7 mutants on myogenesis. Expression of nuclear-retained HDAC7 mutants signiﬁcantly
inhibits myogenesis in C2C12 cells and reduces the expression of muscle-speciﬁc myosin heavy chain (MHC)
and myogenin. The inhibition in myocyte differentiation can be partially relieved by introduction of a
mutation disrupting HDAC7:MEF2 interaction. Since phosphorylation of HDAC7 plays an important role in its
nucleocytoplasmic shuttling, we further investigated the expression and distribution of phosphorylated
HDAC7. To our surprise, the phosphorylation levels of HDAC7 at S344 and S479 were slightly decreased upon
differentiation, whereas the phosphorylation of S178 was unchanged. Interestingly, a signiﬁcant fraction of
pS344- and/or pS479-HDAC7 localized to plasma membrane of myotubes. In addition, Ser178-phosphory-
lated (pS178) HDAC7 displays a predominately actin ﬁlament-like structure before muscle differentiation.
Consistent with this notion, HDAC7 partially colocalized with actin ﬁlaments; in particular, pS178-HDAC7
largely colocalized with actin ﬁlaments as indicated by phalloidin counter staining in myocytes. Furthermore,
C2C12 cells expressing nuclear-retained HDAC7 display defects in migration. Our results provide novel
insight into the mechanisms that regulate myocyte differentiation and migration by controlling the
subcellular distribution of HDAC7 in differentiating myoblasts.land, OH 44106, USA. Tel.: +1
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Class IIa HDACs, HDAC4, -5, -7, and -9, are abundantly expressed in
cardiac and skeletal muscle [1–3] and are mistakenly thought to
function interchangeably. They contain a highly conserved catalytic
domain but differ widely outside this region. All class IIa HDACs can
repress transcriptional activity of myocyte enhancer factor-2 (MEF2)
proteins [4–11]. MEF2s play important roles during muscle differenti-
ation [12–17] by upregulatingmany keymuscle-speciﬁc genes. Class IIa
HDACs are subjected to regulation by covalent modiﬁcation and
nucleocytoplasmic trafﬁcking [18]. As such, control of their subcellular
localization may constitute an essential mechanism to regulate muscle
differentiation.
Skeletal muscle differentiation is an ordered, temporal process that
canbe recapitulated in vitro [19,20]. Earlier studies ofHDAC4andHDAC5in C2C12 myoblast differentiation suggest that their subcellular
localization during myoblast differentiation is subjected to distinct
regulation. HDAC5 is distributed in both the nucleus and the cytoplasm
of myoblasts but is localized exclusively in the cytoplasm of multinu-
cleated myotubes and mislocalization of HDAC5 inhibits myoblast
differentiation [21]. In contrast, HDAC4 is predominantly localized in the
cytoplasm of myoblasts and translocates into the nucleus in differen-
tiated myotubes [16,22]. These studies suggest that HDAC4 and HDAC5
are differentially regulated and may have distinct functions and also
highlight the importance of the mechanisms underlying the subcellular
localization of class IIa HDACs during myocyte differentiation.
Nucleocytoplasmic shuttling of class IIa HDACs involves dynamic
interplay between nuclear import and export. In addition, we have
recently shown that in response to extracellular signals, sequestration
of HDAC7 to PML NBs may represent a subnuclear mechanism that
prevents HDAC7 from repressing the expression of its target genes
[23]. Nuclear localization of class IIa HDACs is mediated through a
nuclear localization sequence (NLS) and their association with
importin α [21,24–26]. Phosphorylation of class IIa HDACs at
conserved serine residues by kinases such as CaMK I/IV [5], protein
kinase D (PKD) [27–30], Mirk/dyr1B [31], (MARK)–Par-1 kinase [32],
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nuclear export, thereby increasing their cytoplasmic accumulation
[5,25]. This is likely achieved through the association of class IIa
HDACs with 14-3-3 family proteins. Unphosphorylatable class IIa
HDACs fail to interact with 14-3-3 proteins and are preferentially
localized in the nucleus. This observation is consistent with the notion
that 14-3-3 binding blocks the recognition of the nearby NLS on class
IIa HDACs to inhibit their nuclear import [26].
We and others have shown that a C-terminal nuclear export
sequence (NES) is absolutely essential for nuclear export of class II
HDACs [5,21,26,34]. Treatment of cells with leptomycin B (LMB), a
CRM1-speciﬁc inhibitor, or mutations at the NES restrict localization
of class II HDACs to the nucleus [5,25]. Furthermore, overexpression of
CRM1 potently promotes cytoplasmic localization of wild-type
HDAC7 and the unphosphorylatable mutant, S/A, but not the NES
mutant in HeLa cells [26]. These data suggest that phosphorylation at
S178, S344, and S479 is not essential for cytoplasmic localization of
HDAC7.
Despite the importance of the role of phosphorylated class II
HDACs in myocyte differentiation, little is known in the dynamics of
their subcellular distribution. In this study, we have examined the
subcellular distribution of endogenous HDAC7 and phosphorylatedFig. 1. Subcellular localization of HDAC7 during myogenesis. (A) The expression levels of HD
cells were harvested at the indicated times. Whole-cell extracts were prepared and subject
relative expression levels of HDAC7 at day 0, 2, or 4 after differentiation are normalized
differentiated myotubes. Undifferentiated myocytes (D0) and differentiated myotubes (D
methods. Cytoplasmic and nuclear fractions of equal cell numbers were loaded followed
antibodies. (C) Undifferentiated C2C12 myoblasts were stained with anti-HDAC7 and anti-M
were ﬁxed and stained at days 3 (D) and 5 (E) with DAPI (blue) and antibodies against muscl
arrow marks a myocyte that expresses MHC with nuclear HDAC7 staining. Scale bars: 20 μm
MHC antibody staining; panel d: merged image of DAPI and anti-HDAC7 antibody staining; p
image of DAPI and anti-MHC antibody staining.class II HDACs during myocyte differentiation. To our surprise,
phosphorylation of HDAC7 was not increased during myocyte
differentiation. We further generated stable cell lines that constitu-
tively express wild-type or HDAC7 mutants and examined their
effects on myocyte differentiation. Our studies detail the mechanism
underlying the subcellular distribution and establish unique require-
ments of HDAC7 in myoblast migration and myotube formation.
2. Materials and methods
2.1. Plasmid construction
HDAC7 expression plasmids, CMX-FLAG-mHDAC7 (S/A which is
S178A/S344A/S479A), CMX-FLAG-mHDAC7 (mNES), CMX-FLAG-
mHDAC7 (AWA which is D692A/D694A) and CMX-FLAG-mHDAC7
(DNLS, in which amino acids 183–212 were removed) have been
previously described [5,26,35]. Site-directed mutagenesis was carried
out to generate HDAC7 (SNwhich is S/A+mNES), HDAC7 (SNLwhich
is S/A+mNES+L112A), and HDAC7 (SNA which is S/A+mNES+
AWA) according to manufacturer's protocol (Stratagene). The pBabe-
FLAG-mHDAC7 expression plasmids and their mutant derivatives
were generated from PCR reactions using CMX-FLAG-mHDAC7 asAC7 during C2C12 differentiation. C2C12 myoblasts were induced to differentiate and
ed to immunoblotting with anti-MHC, anti-HDAC7, and anti-α-tubulin antibodies. The
by α-tubulin and are shown. (B) Subcellular fractionation of C2C12 myocytes and
4) were harvested and subcellular fractions prepared as described in Materials and
by SDS–PAGE and Western blotting with anti-HDAC7, anti-Lamin B, or anti-GAPDH
HC antibodies followed by confocal microscopy. Upon induction of differentiation, cells
e-speciﬁc myosin heavy chain (MHC) (red) followed by confocal microscopy. The white
. For C–E, panel a: anti-HDAC7 antibody staining; panel b: DAPI staining; panel c: anti-
anel e: merged image of anti-HDAC7 and anti-MHC antibody staining; panel f: merged
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manufacturer's protocol (Invitrogen). All constructs were veriﬁed by
DNA sequencing.
2.2. Antibodies
HDAC7 antibodies and their properties have been previously
described [23,26,36]. The speciﬁcity of the phospho-antibodies has
been previously examined in HeLa cells [26] and is also examined in
C2C12 myocytes in Supplementary Fig. 3. Anti-α-tubulin antibody was
purchased from Roche (2013819), while anti-FLAG (F3165) antibodies
were purchased from Sigma. Anti-actin antibodieswere purchased fromFig. 2. Subcellular distribution of transfected YFP-HDAC7. (A) Wild-type (WT) and muta
myoblasts followed by immunoﬂuorescence microscopy. Panels a–c: YFP alone, panes d–f: YF
m–o: YFP-HDAC7 (S/A). (B) The effects of the expression of CaMK and CRM1 on subcellular d
indicated. Scale bars: 20 μm.Santa Cruz (sc-1615, sc-8432, and sc-10731) or Sigma (A5441).
Rhodamin-conjugated phalloidin was purchased from Cytoskeleton
(PHDR1). The myosin heavy chain (MHC) antibody (MF20) was
purchased from Developmental Studies Hybridoma Bank, Iowa City, IA.
Anti-myogenin antibodies were purchased from Santa Cruz (sc-12732).
2.3. C2C12 proliferation and differentiation
Differentiation of parental and stable C2C12 myoblasts was carried
out following the same protocol. Monolayers of C2C12 myoblasts and
stably transfected derivatives were maintained in growth medium
(GM) consisting of Dulbecco's modiﬁed Eagle's medium (DMEM) andnt HDAC7 YFP-HDAC7 expression plasmids were transiently transfected into C2C12
P-HDAC7 (WT), panels g–i: YFP-HDAC7 (DNLS), panels j–l: YFP-HDAC7 (mNES), panels
istribution of YFP-HDAC7. The expression plasmids transfected into C2C12myocytes are
Fig. 3. The effects of HDAC7mutations on the ability of HDAC7 to inhibit myogenesis. C2C12 cells stably expressing vector alone, HDAC7 (WT), HDAC7 (S/A), HDAC7 (mNES), HDAC7
(SN), or HDAC7 (SNL) were grown to 80% conﬂuence and induced for differentiation as described in Materials and methods. Cells were ﬁxed and stained at days 2 (A) and 4 (C) with
DAPI (blue) and antibodies against muscle-speciﬁcMHC (red) followed by ﬂuorescence microscopy. Representative images obtained from two independent clones of each stable cell
line are shown. (B) The average number of cells expressing MHC per 100 cells at day 2. (D) The average number of nuclei per myotubes at day 4. The p values of statistical t-test
comparing C2C12 cells expressing wild-type HDAC7 or mutant proteins recorded under the same conditions are shown (*pb0.05, **pb0.01, or ***pb0.001). NS: not signiﬁcant.
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achieved by replacing the growthmediumwith differentiatingmedium
(DM) (DMEM, 2% horse serum, and 1% penicillin streptomycin) when
the cells reached 80% conﬂuence. The cells were fed once every 2 days
thereafter until harvesting.
2.4. Subcellular localization of transiently transfected HDAC7 in C2C12
cells
C2C12 myoblasts were transiently transfected with YFP, YFP-
HDAC7 (WT), or mutant YFP-HDAC expression plasmids followed by
confocalmicroscopy. To evaluate the effects of CaMK and CRM1 on the
subcellular distribution of HDAC7, an empty vector, CaMK, or CRM1
expression plasmid was cotransfected with wild-type or mutant
HDAC7 expression plasmid.
2.5. Generation of stable C2C12 cells expressing HDAC7 mutants
C2C12 myoblasts were stably transfected with pBabe-FLAG-
HDAC7 (WT) or the HDAC7 mutants described above to generate
the cell lines C2C12-FLAG-HDAC7. The C2C12-pBabe (vector alone)
cell line was used as a negative control in which C2C12 myoblasts
were stably transfected with the empty vector (pBabe-3F vector).
After transfection, stable cells were selected on puromycin (2 μg/ml)
for 10 days. The stable cell lines are maintained in GM+0.5 μg/ml
puromycin. For differentiation, cells were grown to 80% conﬂuence
and switched to DM+0.5 μg/ml puromycin for up to 5 days.
2.6. Immunoﬂuorescence and confocal microscopy
C2C12 cells were washed in 1× PBS, ﬁxed for 30 min with freshly
prepared 3.7% paraformaldehyde in PBS. Fixed cells werewashedwith
1× PBS, followed by permeabilization with a 10-min treatment withFig. 4. Expression of MHC and myogenin in HDAC7 nuclear mutants. Whole-cell extracts of
performed to detect expression of exogenous FLAG-HDAC7 (A) or total HDAC7 (B). Who
Immunoblotting was performed to detect expression of HDAC7, MHC, and myogenin (C). Th
day 4 (D) were quantiﬁed by Photoshop software. The ratio of [MHC]/[α-tubulin] and [mypermeabilization buffer (10% goat serum, 1% Triton X-100, 1× PBS).
After 1 hour of incubation with a blocking buffer (10% goat serum,
0.5% Tween 20, 1× PBS), cells were incubated for 2 hours with the
indicated antisera diluted 1:500 in blocking buffer. Samples were
washed three times with 1× PBS, mounted for microscopy in
mounting solution with DAPI (Vector Laboratories, Inc.) and stained
with anti-FLAG, anti-HDAC7 or anti-phosphorylated HDAC7 antibo-
dies and MHC antibodies. Following primary antibody incubation,
samples were incubated with ﬂuorochrome-coupled secondary
antibodies (anti-rabbit Alexa Fluor 488 or anti-mouse Alexa Fluor
594 from Invitrogen). Fluorescence and confocal microscopy were
conducted according to our previously published protocols [36].2.7. Preparation of whole-cell lysates and immunoblotting
C2C12 myoblasts or myocytes were harvested, lysed in NETN
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 10% glycerol, 0.5% NP-40,
1 mM PMSF, phosphatase inhibitor cocktail (Roche), and protease
inhibitor cocktail (Roche)) for 15 min at 4 °C, scraped, and centrifuged
15 min at 13,000 rpm. The cell lysates were loaded onto SDS–PAGE
gels and then transferred to a nitrocellulose membrane. The proteins
of interest on the membrane were detected using the indicated
antibodies by Western blotting. To determine phosphorylation of
HDAC7, whole cell extracts were probed with anti-HDAC7, anti-
pS178, anti-pS344, or anti-pS479 antibodies.2.8. Subcellular fractionation of myocytes and myotubes
Myocytes and myotubes were collected at days 0 (D0) and 4 (D4)
after grown in differentiation medium, respectively. Subcellular
fractionation of cell lysates was performed according to a published
protocol [37].HDAC7 wild-type and mutants were prepared at days 0, 2, and 4. Immunoblotting was
le-cell extracts of HDAC7 wild-type and mutants were prepared at days 0, 2, and 4.
e relative expression levels of MHC (white column) and myogenin (shaded column) at
ogenin]/[α-tubulin] of HDAC7 (WT) at day 4 was set at 1.
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The expression of GST-MEF2A (1–86) and GST-MEF2A (1–243)
fusion proteins and GST pull-down assays were carried out accordingFig. 5. The effects of HDAC7 NLS deletion and catalytic mutation on myogenesis. C2C12 myob
to 80% conﬂuence and induced for differentiation. Cells were ﬁxed and stained at days 2 (A)
(MHC) (red) followed by ﬂuorescence microscopy. Representative images from two inde
expressing MHC per 100 cells at day 2. (D) The average number of nuclei per myotubes at da
not signiﬁcant. (E) Expression of exogenously expressed HDAC7 (SNA) in C2C12 cells. Westo our previously published protocol [38]. Immobilized GST fusion
proteins were incubated with HA-HDAC7 (SN) or HDAC7 (SNL)
expressed in C2C12 myocytes. The pull-down fractions were
subjected to Western blotting with anti-HA antibody.lasts stably expressing wild-type, mutant HDAC7 (ΔNLS), or HDAC7 (SNA) were grown
and 4 (C) with DAPI (blue) and antibodies against muscle-speciﬁc myosin heavy chain
pendent clones of each stable cell lines are shown. (B) The average number of cells
y 4. The p values of statistical t-test are shown (*pb0.05, **pb0.01, or ***pb0.001). NS:
tern blotting was performed similar to that of Figs. 4A and B.
Fig. 6. Phosphorylation of class II HDACs during C2C12 differentiation. C2C12whole-cell
extracts harvested at the indicated days after the induction of differentiation were
prepared. Whole-cell lysates were subjected to Western blotting with anti-pS178, anti-
pS344, and anti-pS479 antibodies. Relative levels ([phosphorylated HDAC7 at day 4]/
[phosphorylated HDAC7 at day 0]) of phosphorylated HDAC7 at S178, S344, or S479 in
differentiated myotubes, and undifferentiated myocytes are normalized by actin and
are shown at the bottom of each lane. The experiment was repeated three times. A
representative image is shown. The slower migrating species likely to be other
members of class IIa HDACs because phospho-antibodies cross react with other class IIa
HDACs.
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C2C12 stable cells were grown to monolayer 100% conﬂuence and
scratched vertically with a sterile 100-μl pipette tip. Cells were then
washed twice to remove cellular debris and incubated in the same
growth medium. To standardize the position of the wound for
photography, short lines were marked underneath the plates. The
same wound ﬁelds were observed and images taken under micro-
scope (TELAVAL31, ZEISS, Germany) equipped with a SPOT LIGHT
camera (Model 3.2.0) at 0 and 7 hours after wounding. The
percentage of migration was then calculated by using Photoshop to
measure the width of the clear zone. The percent migration at 7 hours
was calculated by subtracting the width of the scratch at 7 hours from
the total width of the scratch at 0 hour, divided by the total width at
0 hour multiplied by 100.
3. Results
We have previously shown that mouse HDAC7 is highly expressed
in cardiac and skeletal muscle [2], implying that it has a physiological
role inmuscle. To test this, we ﬁrst examined the expression of HDAC7
during C2C12 myocyte differentiation and found that the expression
levels of HDAC7 during differentiation at days 0, 2, and 4 were
relatively constant (Fig. 1A). To investigate whether the subcellular
distribution of HDAC7 is altered during C2C12 differentiation, we
performed subcellular fractionation of C2C12myocytes andmyotubes
and found that no nuclear HDAC7 was detected in differentiated
myotubes (Fig. 1B). We further carried out immunostaining and
confocal microscopy in C2C12 myoblasts and myotubes. At day 0,
before the induction of differentiation, HDAC7 was localized both in
the nucleus and in the cytoplasm (Fig. 1C, panels a–f). C2C12 cells
were induced to differentiate by serum withdrawal for up to 5 days.
Differentiation of myoblasts was evaluated by monitoring the
expression of myosin heavy chain (MHC). Terminally differentiated
myotubes were determined by their multinucleate phenotype. Upon
differentiation, HDAC7 was redistributed primarily to the cytoplasm
of myotubes from a nascent stage (with an average of 4 nuclei per
myotube) at day 3 to a mature stage (with more than 50 nuclei per
myotube) at day 5 (Figs. 1D and E). In the majority of C2C12 cells that
express MHC, HDAC7 was exclusively localized in the cytoplasm.
However, a few cells remained that displayed MHC staining with
nuclear HDAC7 (Fig. 1D, white arrow). We also noticed that HDAC7
was localized to the cytoplasmic membrane in some myotubes (see
below). Overall, these results demonstrate that muscle differentiation
coincides with HDAC7 redistribution to the cytoplasm.
To characterize the regulation of HDAC7 subcellular distribution
in C2C12 cells, YFP-HDAC7 (WT) or mutants transiently transfected
into C2C12 myoblasts and their subcellular localizations were
examined by confocal microscopy. Consistent with previous reports
in HeLa cells [26], YFP-HDAC7 (WT) was mostly nuclear with a small
fraction of the protein in the cytoplasm (Fig. 2A, panels a–f). Deletion
of the NLS (DNLS) caused a redistribution of HDAC7 to the cytoplasm
(Fig. 2A, panels g–i). In addition, mutations in the NES (mNES)
resulted in accumulation of HDAC7 in the nucleus, whereas a
phosphorylation site mutant (S/A) exhibited a similar staining
pattern to that of the wild-type protein (Fig. 2A, panels j–o). To
examine the effects of CRM1 and CaMK on the subcellular
distribution of HDAC7, we coexpressed wild-type (WT) or mutant
YFP-HDAC7 with constitutively active CaMK or CRM1 [26] (Fig. 2B).
Overexpression of either CRM1 or CaMK promoted cytoplasmic
retention of YFP-HDAC7 (WT) (panels a–i), while only CRM1
promoted nuclear export of YFP-HDAC7 (S/A) (panels j–o), but not
YFP-HDAC7 (mNES) (panels p–r, Supplementary Fig. 1). Taken
together, these data demonstrate that CRM1 stimulates cytoplasmic
retention of HDAC7 and that the C-terminal NES is essential for
CRM1-mediated HDAC7 nuclear export. In addition, phosphorylationof S178, S344, or S479 enhances cytoplasmic retention of HDAC7 but
is not sufﬁcient to do so in the absence of a functional NES. These data
are also consistent with our observation reported earlier in HeLa
cells [26].3.1. Mutation at the C-terminal NES of HDAC7 inhibits myocyte
differentiation
To examine whether altered cellular distribution of HDAC7
affects muscle differentiation, we tested the effects of HDAC7
mislocalization on myogenesis. C2C12 cells were stably transfected
with wild-type HDAC7 (WT) or HDAC7 mutant expression con-
structs. The subcellular localization of the stably expressed wild-type
or mutant HDAC7 in undifferentiated myocytes was examined by
immunoﬂuorescene microscopy using anti-FLAG antibodies (Sup-
upplementary Fig. 2A). The subcellular localization of stably
transfected HDAC7 mutants exhibited similar distributions to those
of the transiently transfected proteins except for the stably
expressed wild-type HDAC7 protein, which exhibited more cyto-
plasmic distribution than transiently transfected proteins in undif-
ferentiated myocytes. Differentiation assays were performed to
investigate the ability of these C2C12 cell lines to differentiate into
myotubes. Focusing ﬁrst on the 2-day samples, we noted that there
were no detectable differences in differentiation between C2C12-
FLAG (vector) and C2C12 FLAG-HDAC7 (WT) stable cells (Fig. 3A,
panels a–f, and Supplementary Fig. 2B). However, the stable
expression of FLAG-HDAC7 (mNES) signiﬁcantly decreased the
number of differentiating cells at day 2 of myogenesis (panels g–I
and Fig. 3B). In addition, the stable expression of FLAG-HDAC7 (S/A)
moderately reduced the amount of differentiating myoblasts (panels
j–l and Fig. 3B). To examine whether the combined mutations (S/A
and N) will affect myogenesis additively, we generated another
HDAC7 mutant FLAG-HDAC7 (SN or S/A+mNES). This mutant
repressed the myogenesis at day 2 to a similar extent as FLAG-
HDAC7 (mNES).
To examine whether the nuclear retained HDAC7 (SN) mutant
impairs myogenesis through its transcriptional repression activity on
MEF2 transcription factors, we generated a mutant HDAC7, HDAC7
(SNL) that contains an additional mutation, L112A, which abolishes its
interaction with MEF2A ([38], Supplementary Fig. 4). We found that
the additional L112A mutation partially rescued the myogenesis
deﬁciency in C2C12-FLAG-HDAC7 (SN) (Figs. 3A and B).
1193C. Gao et al. / Biochimica et Biophysica Acta 1803 (2010) 1186–1197At day 4, stable expression of HDAC7 (mNES), and HDAC7 (SN),
but not HDAC7 (S/A), signiﬁcantly reduced the size of the myotubes
(Figs. 3C and D). In contrast, the C2C12 cells stably expressing HDAC7
(SNL) mutant had more myotubes than C2C12-FLAG-HDAC7 (SN)
cells. Nonetheless, the number of nuclei per myotube in C2C12-FLAG-
HDAC7 (SNL) was signiﬁcantly lower than that in C2C12-FLAG-
HDAC7 (WT). MEF2 has been shown to regulate the expression of
genes involved in myogenesis including myogenin. To test whether
HDAC7mutants defective in differentiation are also impaired in MEF2
target gene expression, we ﬁrst examined the expression ofFig. 7. Subcellular localization of phosphorylated class IIa HDACs inmyoblasts and differentia
with anti-pS178, anti-pS344 and anti-pS479 antibodies followed by confocal microscopy. N
before and after muscle differentiation. Induction of myoblast differentiation was performed
antibody staining; panel b: DAPI staining; panel c: anti-MHC antibody staining; panel d: mer
of anti-phospho-HDAC7 and anti-MHC antibody staining; panel f: merged image of DAPI anexogenous HDAC7 and found that the expression levels of stably
transfected HDAC7 (S/A), HDAC7 (mNES), or HDAC7 (SN) were
comparable to or lower than that of the wild-type HDAC7 (Figs. 4A
and B). We next measured myogenin expression of wild-type and
HDAC7 mutants, mNES and S/A, at days 0 and 4. Figs. 4C and D show
that HDAC7- (mNES) and HDAC7- (SN) expressing cells have lower
levels of myogenin as well as MHC, a differentiation marker. In
summary, these data demonstrated that stable expression of
constitutively nuclear HDAC7 mutants, mNES or SN, impairs myo-
genic gene expression and blocks C2C12 differentiation.ted myotubes. Undifferentiated (A–C) and differentiated (D–F) C2C12 cells were stained
ote that α-pS178 antibodies costained with actin ﬁlaments and the plasma membrane
as described inMaterials andmethods. Scale bars: 20 μm. Panel a: anti-phospho-HDAC7
ged image of DAPI and anti-phospho-HDAC7 antibody staining; panel e: merged image
d anti-MHC antibody staining.
Fig. 8. pS178-HDAC7 colocalizes with actin ﬁlaments. (A) HDAC7 partially colocalizes
with actin ﬁlaments in C2C12 cells. (B) pS178-HDAC7 colocalizes with actin ﬁlaments.
Immunostaining was carried out as in Fig. 1 except that the cells were not conﬂuent.
Note that DAPI and HDAC7 staining were taken from two different sections. Scale bars:
20 μm. Panel a: anti-HDAC7 antibody staining; panel b: DAPI staining; panel c: anti-
MHC antibody staining; panel d: merged image of DAPI and anti-HDAC7 antibody
staining; panel e: merged image of anti-HDAC7 and anti-MHC antibody staining; panel
f: merged image of DAPI and anti-MHC antibody staining. (C) HDAC7 and actin
associate in C2C12 cells. Whole-cell lysates prepared from C2C12 myocytes collected at
day 0 before switching to differentiation medium were subjected to coimmunopreci-
pitation with beads alone or the indicated antibodies followed byWestern blotting with
the indicated antibodies.
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inhibition of myocyte differentiation
We further examined the effects of the NLS on C2C12 differenti-
ation and found that stable expression of HDAC7 (DNLS) did not affect
C2C12 differentiation (Fig. 5). We had previously shown that a
D692A/D694A mutant ablates the ability of HDAC7 to deacetylate
histones [35]. To determine whether the intrinsic HDAC activity is
essential for HDAC7 inhibition of C2C12 differentiation, we generated
a cell line that stably expresses a nuclear export-defective, nonpho-
sphorylatable deacetylase-defective HDAC7 (SNA). We found that
stable expression of HDAC7 (SNA) still inhibited C2C12 differentia-
tion. The inhibitory effect of HDAC7 (SNA) on differentiation was not
due to its higher expression (Fig. 5E). These results indicated that the
HDAC catalytic activity is not required for HDAC7 to inhibit C2C12
differentiation.
3.3. The phosphorylation level of HDAC7 at S178, S344, or S479 during
myocyte differentiation
Phosphorylation of HDAC7 at S178, S344, or S479 enhances the
binding between HDAC7 and 14-3-3 and promotes subsequent
cytoplasmic accumulation of HDAC7 [5,27]. Wild-type HDAC7 also
redistributes to the cytoplasm and membranes during muscle
differentiation. To investigate the role of phosphorylation of HDAC7
during muscle differentiation, we ﬁrst examined the phosphorylation
status of endogenous HDAC7 by carrying out immunoprecipitations
followed by immunoblotting using various antibodies (anti-HDAC7,
anti-pS178, anti-pS344, and anti-pS479). We found that the phos-
phorylation level of HDAC7 at S178 in undifferentiated and differen-
tiated C2C12 remained almost the same (Fig. 6). To our surprise,
phosphorylation of HDAC7 at S344 and S479 was slightly decreased
upon differentiation.
3.4. Subcellular distribution of phosphorylated class II HDACs during
myocyte differentiation
We further determined the subcellular distribution of phosphor-
ylated HDAC7 during muscle differentiation. We have previously
generated phosphospeciﬁc antibodies against phosphorylated HDAC7
at S178, S344, and/or S479 and conﬁrmed their speciﬁcity. However,
because of the high sequence conservation at these phosphorylation
sites, these phosphospeciﬁc antibodies cross react with other class IIa
HDACs (HDAC-4, -5, and -9) [26]. Before induction of differentiation,
class IIa HDACs phosphorylated on S178 or S479 were primarily
localized in the cytoplasm (Figs. 7A–C). Of note, a signiﬁcant fraction
of pS178-phosphorylated class IIa HDACs showed an actin ﬁlament-
like distribution pattern in myoblasts. In contrast, class IIa HDACs
phosphorylated on S344were distributed evenly between the nucleus
and the cytoplasm of the myoblasts (Fig. 7B). Upon induction of
differentiation, pS178-, pS344-, and pS479-phosphorylated class IIa
HDACs localize in the cytoplasm and the cytoplasmic membrane of
the differentiated cells (Figs. 7D and E). In summary, these data
demonstrate that phosphorylation of class IIa HDACs coincides with
their cytoplasmic localization during myogenesis.
To further conﬁrm that pS178-phosphorylated class IIa HDACs
were localized to actin ﬁlaments, we performed additional immuno-
ﬂuorescence microscopy. C2C12 cells were costained with anti-
HDAC7 antibody and rhodamine-conjugated phalloidin, a marker for
actin ﬁlaments. We found that a signiﬁcant fraction of HDAC7
colocalized with actin stress ﬁbers (Fig. 8A). An even more
pronounced staining pattern was observed when anti-pS178 anti-
bodies were used for immunostaining. In this case, the majority of
pS178-phosphorylated class IIa HDACs colocalized with actin stress
ﬁbers (Fig. 8B). We further investigated the nature of the colocaliza-
tion, by coimmunoprecipitation experiments, and found that HDAC7and actin interact in C2C12myocytes (Fig. 8C). In summary, these data
indicate that HDAC7 colocalizes and associates with actin ﬁlaments.
3.5. HDAC7 mutants inhibit myoblast migration
Cell migration is an important step for myoblast fusion to form
myotubes. Our observation that HDAC7 is localized to the actin
ﬁlaments and plasma membranes suggests that HDAC7 may play a
role in cell migration. To test this, we assayed cell migration of the
HDAC7 mutant stable cell lines in a migration assay. As shown in
Fig. 9, C2C12 myoblasts expressing the HDAC7 (S/A) mutant did not
signiﬁcantly differ from the cells expressingwild-type HDAC7 protein.
Fig. 9. The effect of HDAC7 mutations on migration of C2C12 myoblasts. (A) The HDAC7 mNES mutant inhibits migration in conﬂuent myoblasts. Myoblasts stably integrated with
wild-type or mutant HDAC7were grown to conﬂuence, and wounds were generated andmeasured. Seven hours later, the width of the woundwas determined. A total of six wounds
were used to calculate the percent migration for each stable cell line. A representative image is shown. (B) Quantitative analysis of cell migration. The data were derived from six
independent ﬁelds and are representative of two independent experiments.
1195C. Gao et al. / Biochimica et Biophysica Acta 1803 (2010) 1186–1197In contrast, cells expressing HDAC7 (mNES) or HDAC7 (SN) exhibited
signiﬁcant deﬁcits in myoblast migration. Furthermore, HDAC7 (SNL)
showed a better migration than that of HDAC7 (SN). These data
suggest that nuclear retention of HDAC7 not only inhibits myogenesis
but also impairs myoblast migrationmost likely through its regulation
of MEF2s.
4. Discussion
Ourpresent studydemonstrates that endogenousHDAC7 is localized
in both the nucleus and the cytoplasm inundifferentiatedmyoblasts but
becomes exclusively cytoplasmic in terminally differentiatedmyotubes.Fig. 10. A summary of the effect of HDAC7 mutations on C2C12 myocyte differentiation an
HDAC7 mutants used in this study are described in the text and indicated, and their effectsFurthermore, phosphorylated formsof class IIHDACs, as recognized bya
cross-reactingphosphospeciﬁc antibody, are predominantly localized in
the cytoplasm of terminally differentiated myotubes. Unexpectedly,
phosphorylation of HDAC7 at S344 and S479 is slightly decreased upon
induction of differentiation. We also show that a nuclear export-
defective mutant of HDAC7 (mNES), but not the phosphorylation-
defective mutant (S/A), impairs myotube formation and cell migration
of C2C12 myoblasts, Taken together, our data establish the signiﬁcance
of HDAC7 subcellular distribution and imply that the redistribution of
HDAC7 is an important event during myogenesis.
Muscle differentiation is a tightly regulated process, which is
controlled by a network of proteins involved in signal transductiond migration. A schematic representation of HDAC7 functional domains is shown. The
on myocyte differentiation and migration are summarized.
1196 C. Gao et al. / Biochimica et Biophysica Acta 1803 (2010) 1186–1197and transcriptional regulation [39]. MEF2 transcription factors are the
central players in this network through their effects on gene
expression and associations with other myogenic transcription
factors. MEF2s transmit signals from membranes to downstream
genes by switching binding partners between corepressors and
coactivators to regulate transcription or vice versa [40]. In this
study, we show that HDAC7 is retained in the cytoplasm during
myocyte differentiation. This leads to the derepression of MEF2-
targeted myogenic genes such as myogenin and thus promotes the
muscle differentiation process. Using a set of HDAC7 mutants that are
defective in nuclear localization, nuclear export, or its ability to
interact with 14-3-3 proteins (Fig. 10), we have identiﬁed sequences
that are critical for myocyte differentiation.We have found that C2C12
cells stably expressing HDAC7 (mNES) or HDAC7 (SN) display severe
defects in myogenic gene expression and myotube formation (Fig. 3).
However, a mutation (L112A) that abolished the association between
HDAC7 and MEF2 [38] partially restored the normal differentiation of
C2C12 cells. L112Amutant abolishes interactions between HDAC7 and
MEF2 and interactions between HDAC7 and alpha actinin 4 (ACTN4)
[38]. It is possible that nuclear HDAC7 inhibits myogenesis by
repressing the transcriptional activity of MEF2 in the nucleus.
However, we cannot rule out the possibility that the interaction
between HDAC7 and ACTN4 may be also involved in myogenesis.
Interestingly, our data also show that the catalytically dead mutant
HDAC7 (D652A/D654A)modestly affects the ability of HDAC7 (SN) to
inhibit C2C12 differentiation, suggesting that deacetylase activity is
dispensable for HDAC7 to inhibit myogenesis. Therefore, HDAC7 may
exert its effects on myogenesis through other transcription regulatory
motifs. Indeed, we have previously demonstrated that HDAC7 harbors
three potent repression domains and that the loss of the C-terminal
HDAC activity (D562A/D654A) does not completely abrogate its
repression activity [2]. Further support for this result has come from
several reports demonstrating that the N-terminal region of class IIa
HDACs associates with other transcriptional corepressors including
CtBP1 [41] and HP1 [42]. This suggests that the N-terminal
noncatalytic domain of HDAC7 can potently repress transcription,
even when HDAC catalytic activity is defective.
We demonstrated an attenuation of HDAC7 phosphorylation at
S344 and S479 4 days after differentiation, whereas no change at
S178. Immunoﬂuorescence microscopy consistently demonstrated
that the intensity of phosphorylated class II HDACs was comparable
for undifferentiated and differentiated C2C12 cells. These observa-
tions suggest that the level of HDAC7 phosphorylation at these
residues does not correlate with the cytoplasmic accumulation of
HDAC7 during C2C12 differentiation. This is consistent with our
observation that overexpression of CRM1 is capable of promoting
cytoplasmic retention of the HDAC7 (S/A) mutant [26] (Fig. 2). One
plausible mechanism is that another factor(s) which is expressed late
(becomes active) during differentiation and blocks nuclear import or
promotes cytoplasmic retention of HDAC7.
The three phosphorylated class IIa HDACs appear to distribute
differently before differentiation (Fig. 7). In undifferentiated myo-
blasts, pS178-HDAC predominantly colocalizes with actin ﬁlaments,
whereas pS344-HDAC and pS479-HDAC localized in both the nucleus
and the cytoplasm. Upon induction of differentiation, all of the
phosphorylated forms of HDACs accumulated in the cytoplasm and
cytoplasmic membranes. These observations raise several questions.
First, why and how does pS178-HDAC7 colocalize with actin
ﬁlaments? We have previously identiﬁed ACTN4, an actin-binding
protein, as an HDAC7 interacting protein. It is possible that ACTN4
may anchor HDAC7 in the cytoplasm [38]. Second, does cytoplasmic
or membrane-bound HDAC7 have a distinct function? It is becoming
increasingly clear, like histone (protein) acetyltransferase (HATs) (or
PATs), that HDACs have nonhistone substrates. Recently, several
laboratories including ours have shown that class II HDACs such as
HDAC4 and HDAC7 are capable of promoting protein sumoylation[36,43–46]. Given these observations, it is possible that class II HDACs
may have distinct activity in the cytoplasm and/or cytoplasmic
membranes.
Before fusion into multinucleated myotubes, myoblasts migrate
and align with each other. The observation that pS178-HDAC7
colocalizes with the actin ﬁlaments and plasma membranes raised
the possibility that HDAC7may regulate and/or interact with the actin
cytoskeleton to inﬂuence cell migration. However, our data demon-
strated that C2C12 cells expressing nuclear-retained HDAC7 (mNES),
but not C2C12 cells expressing phosphorylation-deﬁcient HDAC7 (S/
A), are defective in migration in wound-healing assays. These data
indicate that HDAC7 regulation of myoblast migration depends on the
subcellular localization of HDAC7 but not on the phosphorylation
states of HDAC7. These data also suggest that nuclear-retained HDAC7
may associate with an actin binding factor that is important for the
function of the actin skeleton, such as ACTN4, in the nucleus.
Furthermore, the L112A mutation, which abolishes the interaction
between HDAC7 with either MEF2 or ACTN4, rescued the ability of
HDAC7 (SN) to inhibit cell migration. These observations indicate that
the inability for HDAC7 mutant-expressing C2C12 stable cells to
differentiate correlates with their defects in migration. However, the
details of the mechanism will require further investigation.
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